Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.19 USD
+0.73 (1.90%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Company News for December 28, 2016
by Zacks Equity Research
Companies in the News are: TSLA,PCRFY,IONS,TOSYY,FACU,AMZN
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
Biogen Names Commercial Officer as New CEO, Shares Fall
by Zacks Equity Research
Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.
Ionis (IONS) Receives Milestone Payment from AstraZeneca
by Zacks Equity Research
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.
Top Stocks with Big Potential Catch-Up Moves
by Kevin Matras
Given the recent run-up in the market, here's a screen I've been using recently.